Royalty Pharma plc (RPRX)

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.

Ticker: RPRX
Exchange: Nasdaq
Sector: Healthcare
Industry: Biotechnology
Market cap: $38.60B
52-week range: $37.31 - $69.77

Valuation

Share price: $67.30 (close of Nov 6, 2026)
P/E (TTM): 43.99x
Price to book: 3.94x
Price to free cash flow: 13.04x
Enterprise value: $46.68B
Book value per share: $17.08

Price performance

Period	Change
1 day	-0.40%
5 days	+0.18%
1 month	+19.24%
3 months	+17.53%
6 months	+32.69%
Year to date	+74.17%
1 year	+65.03%
3 years	+142.26%
5 years	+70.29%
All time	+51.24%

Short interest

As of: Oct 15, 2026
Short % of float: 2.92%
Shares short: 12.84M
Days to cover: 4.28
Change since prior report: -0.33%
Source: FINRA consolidated short interest

Profitability and growth

Return on equity: 7.94%
Return on invested capital: 8.35%
Return on assets: 3.93%
Return on capital employed: 8.21%
Net margin: 32.42%
EBITDA margin: 65.74%
Revenue growth: 5.06%
Net income growth: -10.25%
Free cash flow growth: -10.08%

Cash flow and balance sheet

Free cash flow yield (TTM): 7.67%
Current ratio: 1.29x
Net debt to EBITDA: 5.21x

Latest reported year

Period end: Dec 31, 2025
Fiscal year: 2025
Revenue: $2.38B
EBITDA: $1.56B
Net income: $770.95M
Earnings per share: $1.79
Research and development: $452.00M
Interest expense: $307.66M
Shares outstanding: 429.80M

Income statement by year

Period end	Revenue	Gross profit	Net income	EPS
2025-12-31	$2.38B	-	$770.95M	$1.79
2024-12-31	$2.26B	$1.53B	$858.98M	$1.92
2023-12-31	$2.35B	$1.79B	$1.13B	$2.54
2022-12-31	$2.24B	$711.47M	$42.83M	$0.10
2021-12-31	$2.29B	$1.81B	$619.73M	$1.49
2020-12-31	$2.12B	$1.80B	$975.04M	$1.32
2019-12-31	$1.81B	-	$2.35B	$0.00
2018-12-31	$1.79B	-	$1.38B	$0.00
2017-12-31	$1.60B	-	$1.21B	-
2016-12-31	$1.88B	-	$565.91M	-

Margins and returns by year

Period end	Gross margin	Net margin	Return on equity	Return on capital
2025-12-31	-	32.42%	7.94%	8.35%
2024-12-31	67.64%	37.95%	8.31%	7.20%
2023-12-31	76.19%	48.20%	11.25%	9.20%
2022-12-31	31.80%	1.91%	0.45%	1.85%
2021-12-31	79.22%	27.07%	6.05%	8.25%
2020-12-31	84.97%	45.94%	9.85%	10.15%
2019-12-31	-	129.45%	38.24%	21.19%
2018-12-31	-	76.76%	30.27%	12.32%
2017-12-31	-	75.72%	27.13%	8.34%
2016-12-31	-	30.14%	12.73%	6.99%

Cash and debt by year

Period end	Cash	Debt
2025-12-31	$618.70M	$8.57B
2024-12-31	$929.03M	$6.61B
2023-12-31	$477.01M	$6.14B
2022-12-31	$1.71B	$6.12B
2021-12-31	$1.54B	$7.10B
2020-12-31	$1.01B	$5.82B
2019-12-31	$246.20M	$5.96B
2018-12-31	$1.92B	$6.24B
2017-12-31	$1.38B	$6.52B
2016-12-31	$1.67B	$5.72B

Free cash flow by year

Period end	Free cash flow	Stock-based compensation
2025-12-31	$2.49B	$289.89M
2024-12-31	$2.77B	$2.34M
2023-12-31	$2.99B	$2.36M
2022-12-31	$2.14B	$2.17M
2021-12-31	$2.02B	$2.44M
2020-12-31	$2.03B	$5.43M
2019-12-31	$1.67B	-
2018-12-31	$1.62B	-
2017-12-31	$1.42B	-

Dividend history

Most recent payment: Aug 14, 2026
Paid in the last twelve months: $0.92

Payment date	Dividend per share
2026-08-14	$0.23
2026-05-15	$0.23
2026-02-20	$0.23
2025-11-14	$0.22
2025-08-15	$0.22
2025-05-16	$0.22
2025-02-21	$0.22
2024-11-15	$0.21

Investor relations

Past earnings dates

Reported	Fiscal period	EPS estimate
2026-11-04	Sep 2026	$1.18
2026-08-05	Jun 2026	$1.27
2026-05-06	Mar 2026	$1.22
2026-02-11	Dec 2025	$1.33
2025-11-05	Sep 2025	$1.11
2025-08-06	Jun 2025	$1.10
2025-05-08	Mar 2025	$0.99
2025-02-11	Dec 2024	$1.09

Filings and sources

Company website: royaltypharma.com
SEC filings: 10-K, 10-Q and 8-K on EDGAR
Earnings calendar: All upcoming reports

Similar companies

Vertex Pharmaceuticals Inc (VRTX) · Regeneron Pharmaceuticals, Inc. (REGN) · Moderna, Inc. (MRNA) · Incyte Corp (INCY) · Insmed Inc (INSM) · Bio-Techne Corp (TECH) · Thermo Fisher Scientific Inc. (TMO) · Danaher Corp (DHR)

All Healthcare companies

Understanding these figures

Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart

Explore

Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades